In the present invention, there is disclosed a pharmaceutical composition, comprising a thiazolidinedione, metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine.

The invention relates to a pharmaceutical composition for a sustained release, which composition comprises: from 2 to 12 mg of 5-[4-[2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione, optionally as a pharmaceutically acceptable derivative, from 100 to 300 mg of metformin and a pharmaceutically acceptable carrier thereof, where the sustained release is provided by a matrix selected from wherein the sustained release is provided by a sustained release matrix selected from d...

The invention relates to a pharmaceutical composition containing 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine -2,4-dion, optionally in the form of a pharmaceutically acceptable derivative, and metformin capable of ensuring continuous release of at least one of the two active ingredients. The composition is used in medicine, in particular for the treatment of diabetes mellitus of type 2 mainly and the related conditions. The invention relates also to a method for obtaining suc...

A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition for use in the treatment of conditions associated with the pre-diabetic state.

The invention relates to a modified-release pharmaceutical composition in tablet form with enteric coating, which comprises 5-[4-[2-(N-methyl-N-(2-pyridyl)amino) ethoxy]benzyl]tiazolidine-2,4-dione, possibly its pharmaceutically acceptable salt or solvate, and metformin. The composition finds application in medicine, in particular for the treatment of diabetes mellitus, chiefly of type 2, and the conditions related thereto.